A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

Trial Profile

A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Sinapultide (Primary)
  • Indications Neonatal respiratory distress syndrome
  • Focus Adverse reactions
  • Sponsors Windtree Therapeutics
  • Most Recent Events

    • 15 Aug 2017 Status changed from recruiting to discontinued as per sponsor decision to terminate after 3 dosing groups.
    • 22 Jul 2017 This trial has been discontinued in Poland (end date: 2017-07-07)
    • 21 Apr 2017 Planned End Date changed from 1 Mar 2017 to 31 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top